Ipatasertib + Chemotherapy for Cancer
Trial Summary
The trial does not specify if you must stop taking your current medications, but you cannot take medications that are strong inhibitors or inducers of CYP3A enzymes. It's important to discuss your current medications with the trial team to ensure there are no interactions.
Research shows that nab-paclitaxel (Abraxane), a component of the treatment, has been effective in treating metastatic breast and pancreatic cancers, with studies indicating it works well in combination with other drugs and has less toxicity compared to traditional formulations.
12345Ipatasertib has been studied in combination with other drugs like abiraterone for prostate cancer, showing manageable side effects. Paclitaxel, a chemotherapy drug, has known side effects like low white blood cell counts, mild nerve damage, and allergic reactions, but these are often manageable with premedication.
678910The combination of Ipatasertib and Paclitaxel is unique because Ipatasertib targets specific molecular pathways involved in cancer cell growth, potentially enhancing the effectiveness of Paclitaxel, which is a well-established chemotherapy drug. This approach aims to improve treatment outcomes by combining a targeted therapy with traditional chemotherapy.
1112131415Eligibility Criteria
Adults with solid tumors that can't be surgically removed, have spread, and show an AKT genetic mutation. They must have progressed after taxane-based therapy within 6 months and meet specific health criteria including organ function tests. Excluded are those who've had prior AKT inhibitors, certain mutations, uncontrolled illnesses or bowel inflammation, or are pregnant.Participant Groups
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma
- Ovarian cancer
- Breast cancer
- Non-small cell lung cancer
- Kaposi's sarcoma